临床与实验病理学杂志

抽象的

Dramatic Response to Hormone Therapy Plus CDK4/6 Inhibitor of a Retinal Detachment Secondary to Luminal Advanced Breast Cancer

Martín Núñez-Abad, Miguel Ortiz Salvador, Silvia Calabuig-Fariñas, Javier Montero Hernández, Verónica Castro Navarro, Vega Iranzo González-Cruz, Carlos Camps Herrero

Luminal breast cancer is hormone-receptor positive (estrogen-receptor and/or progesterone-receptor positive) and human epidermal growth factor receptor 2-negative (HER2-). Currently, the standard treatment of luminal metastatic breast cancer is the combination of hormone therapy with CDK4/6 (Cyclin-Dependent Kinases 4/6) inhibitors. The overall response rates for the combination are between 40% to 50%, increasing Progression Free Survival (PFS) and Overall Survival (OS) compared with hormone therapy alone. Herein, we report a clinical case showing the management of a patient with luminal breast cancer in different stages of the disease, highlighting the dramatic response of cyclin inhibitor plus fulvestrant to a bilateral retinal detachment due to ocular metastases.